Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month High at $21.42

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $21.42 and last traded at $21.09, with a volume of 7035 shares. The stock had previously closed at $20.07.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several recent research reports. Oppenheimer restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a research report on Wednesday, July 3rd.

Tyra Biosciences Stock Up 4.0 %

The company has a fifty day simple moving average of $17.83 and a two-hundred day simple moving average of $16.86. The stock has a market capitalization of $1.10 billion, a P/E ratio of -12.60 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.11. As a group, equities analysts forecast that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insiders Place Their Bets

In other Tyra Biosciences news, COO Daniel Bensen sold 3,502 shares of Tyra Biosciences stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the transaction, the chief operating officer now directly owns 427,981 shares in the company, valued at $8,559,620. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. raised its stake in shares of Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after purchasing an additional 1,916 shares during the period. AJOVista LLC acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $59,000. Exchange Traded Concepts LLC increased its position in shares of Tyra Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after acquiring an additional 2,417 shares during the last quarter. Fishman Jay A Ltd. MI acquired a new stake in shares of Tyra Biosciences in the first quarter valued at about $246,000. Finally, Victory Capital Management Inc. increased its position in shares of Tyra Biosciences by 53.4% in the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after acquiring an additional 17,490 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.